Early Planning For Cell And Gene Therapy Commercialization: Regulatory, Manufacturing, And Market Access Considerations

Commercialization challenges in cell and gene therapy rarely appear without warning. They trace back to decisions made years earlier, when manufacturers were focused on clinical outcomes and deferred regulatory, manufacturing, and market access planning for later. The window to influence those outcomes is narrower than many development teams expect.

This paper examines the cross-lifecycle considerations that CGT manufacturers need to address during development: when and how to engage regulators in the U.S. and Europe, what evidence to generate with reimbursement in mind, and how supply chain and manufacturing constraints affect launch readiness. The argument is not that every detail must be resolved early, but that deferring these questions carries compounding consequences.

This article offers a structured look at where early planning creates the most leverage. Access it below to see where those decisions are most consequential.